Articles tagged with Cancer Medication
Researchers identified 694 compounds that showed some activity against brain cancer stem cells, including four lead compounds that most successfully inhibited the cells. The study aims to reveal the biology of these stem cells and potentially result in a new therapy for deadly brain cancers.
Researchers at Sanford-Burnham Medical Research Institute have identified a new component of the cellular machinery that senses dietary amino acids, which is essential for mTORC1 activation. This finding provides new information about mTORC1 and its role in cellular metabolism in both normal cells and cancer cells.
Researchers at Thomas Jefferson University have found that two nuclear receptors, EcR/Usp and E75A, work against each other during Drosophila metamorphosis. The study reveals that E75A replaces EcR/Usp to repress genes in the absence of ecdysone hormone.
A study by UCLA's Jonsson Comprehensive Cancer Center found that a combination of chemotherapy and Herceptin significantly increases survival in patients with HER-2 positive breast cancer. The regimen without Adriamycin was comparable to the standard therapy, reducing heart toxicity and acute side effects.
A large study found that daughters of women given diethylstilbestrol during pregnancy face an increased risk of reproductive problems and certain cancers. The study also found a twofold higher risk of infertility and a fivefold increased risk of preterm delivery among DES-exposed women.
Researchers discovered that frequent low-dose administration of chemotherapy medicine topotecan can slow prostate cancer growth without causing side effects. This 'metronomic dosing' alters the cellular activity of the drug, offering a promising new approach to treating slowly growing tumors.
A European Survey of Oncology Nurse Breakthrough Cancer Pain Practices revealed an enormous opportunity to improve pain outcomes through education, with most nurses reporting inadequate training and confusion over medication options. The survey calls for nurse-specific guidelines and training to address the gap in management.
The five-year study aims to determine the medication of choice for preventing migraines in children and teens, addressing a significant gap in evidence-based research. The trial will compare amitriptyline and topiramate, investigating their efficacy and safety profiles in this age group.
Researchers found that later-stage prostate cancer cells lack Pten, a tumor-suppressor gene, leading to rapid cell division and mutations. Plk1 inhibitor BI 2356 showed promise in killing cancer cells without Pten.
Researchers at UCSF Brain Tumor Research Center discovered a protein called NG2 that controls the switch from asymmetric to symmetric cell division in normal cells. This abnormal cell division pattern is associated with oligodendroglioma brain tumors, which may respond to chemotherapy but often recur in resistant forms.
The study found that many people believe cancer is curable, while others hold misconceptions about its causes and treatment options. Research suggests a need for education on the effects of diet and obesity on cancer development.
Researchers found a way to shut down pumps on breast cancer cells' surface that reject chemotherapy drugs, allowing the drugs to penetrate and kill the cells. Activating heat-shock protein Hsp27 forces the pump-action protein P-gp to decrease, making the cells more sensitive to chemotherapy drug Doxorubicin.
Research found that drug company stock prices increased by 13.7% before positive phase III clinical trials and decreased by 0.7% before negative trials. The study also showed that stock prices of established companies with positive trial results were more likely to increase than those of smaller companies with negative trial results.
The Lancet Oncology Commission emphasizes the need for affordable cancer care in high-income countries by addressing issues like overuse, rapid expansion of demand, and shortening life cycles of medical technologies. The commission suggests value-based pricing, personalized medicine, and education to tackle these challenges.
A new study found that couples counseling can significantly improve the sex lives of prostate cancer survivors and their spouses. The therapy was shown to be effective in improving men's sexual function and satisfaction, as well as enhancing their partner's experience.
A new trial suggests that zoledronic acid may extend survival in postmenopausal breast cancer patients by boosting disease-free survival rates. However, the drug's effects on younger women are less clear-cut, with some studies indicating a possible adverse impact on recurrence rates outside bone.
A phase III clinical trial has shown that combining everolimus and exemestane significantly improves progression-free survival for women with advanced breast cancer resistant to hormonal therapy. The combination treatment resulted in an improved survival of nearly seven months compared to women treated with only exemestane.
A Phase II study showed that trastuzumab emtansine (T-DM1) significantly delayed breast cancer progression, improving patients' lives with fewer side effects. The treatment improved time to disease worsening by 41% compared to standard docetaxel chemotherapy plus trastuzumab.
Researchers at Johns Hopkins University have developed a protein switch that instructs cancer cells to produce their own anti-cancer medication. The goal is to deploy a new type of weapon that causes cancer cells to self-destruct while sparing healthy tissue.
A new study found that transplant patients can safely minimize calcineurin inhibitors, reducing toxicity while preventing organ rejection in the short-to-medium period after transplantation. The strategy improves kidney function without causing rejection, offering a safer alternative for some patients.
Researchers found that bortezomib inhibits transforming growth factor beta, a protein essential for scar tissue growth, preventing its development in human cells and mouse models. The drug also prevented expression of proteins necessary for scarring in fibroblast cells from scleroderma patients
Radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]Octreotate has been shown to improve quality of life and reduce tumor size in patients with gastroenteropancreatic or bronchial neuroendocrine tumors. The treatment has been found to have fewer severe side effects compared to other cancer therapies.
A new study suggests that beta-blocker drugs commonly used to treat high blood pressure may also slow the progression of certain serious cancers like melanoma. The review of thousands of medical records in Denmark found patients taking beta-blockers had lower mortality rates and improved survival times.
Researchers at the University of Michigan have identified 10 strategies to help patients understand their cancer treatment options and risks. By using plain language, visualizing risk, and considering frequency over percentages, patients can become more fluent in the language of cancer care and make informed decisions.
A UBC journalism project documents severely constrained access to morphine globally, revealing bureaucratic hurdles and the impact of the war on drugs. The Pain Project showcases stories of patients struggling with pain and caregivers who have fought against intractable systems.
Researchers have discovered that squalamine, a compound isolated from sharks, demonstrates broad-spectrum antiviral activity against human pathogens, including dengue, yellow fever, and hepatitis B, C, and D. The study's findings suggest that squalamine could be explored as a novel human antiviral agent.
Researchers at Case Western Reserve University are studying whether an over-the-counter medication, Glutamine, can ease chemotherapy side effects for people with blood and bone marrow cancers. The study aims to determine if Glutamine will interfere with chemotherapy or yield no benefits for patients diagnosed with multiple myeloma.
A University of Chicago Medical Center expert argues that taking oral anti-cancer medications with food could reduce overdose risks and save patients money. The medication ZYTIGA is a prime example, where taking it with food can increase its effectiveness by up to tenfold.
SuviCa Inc. has partnered with the University of Colorado at Boulder to develop and commercialize a drug screening technology that identifies novel therapies for cancer treatments. The patented tool uses genetically modified Drosophila fruit flies to screen compounds effective against various types of cancer.
Case Western Reserve University School of Medicine has been awarded a $11.3 million grant from the National Cancer Institute to establish a center for research on gastrointestinal cancers. The center will focus on translational research to develop new tests, treatments, and prevention methods for colon and esophageal cancers.
Researchers found that high calcium intake increases prostate cancer risk among African-American men genetically predisposed to poor calcium absorption. This study provides insight into the link between diet and disease, suggesting personalized prevention strategies may be possible in the future.
Researchers found a six-fold increase in pancreatitis cases and a higher rate of pancreatic cancer among patients using sitagliptin and exenatide. The study also suggests a possible link between these drugs and an increased risk of thyroid cancer.
Researchers discovered that genes interact with each other in complex pathways, which can help breast cancer progress. Targeting multiple pathways may lead to more effective combination therapies against the disease. A diuretic used to treat hypertension also showed promise in stopping cancer cell progression.
Researchers at UCLA's Jonsson Comprehensive Cancer Center found that blocking cholesterol uptake in brain cancer cells could provide a new strategy to battle glioblastoma. The study, published in Cancer Discovery, identified the LDL receptor as a key regulator of cancer cell growth and survival.
Researchers at Winship Cancer Institute of Emory University have identified a way to keep the cancer-preventive properties of celecoxib while avoiding its risks. The study shows that celecoxib inhibits an enzyme called GSK3 in lung cancer cells, causing apoptosis and disappearance of a protein called c-FLIP.
A study found that long-term use of nonaspirin anti-inflammatory drugs is associated with an increased risk of renal cell cancer. The study analyzed data from two large prospective cohort studies and found a 51% increase in the relative risk of RCC among those who regularly used nonaspirin NSAIDs for more than four years.
Researchers at Brigham and Women's Hospital have identified a new combination of targeted therapies that successfully treat two aggressive tumor types: neurofibromatosis type 1 and KRAS-mutant lung cancer. The treatment promotes dramatic tumor regression by targeting cancer cells from two different angles.
A study aims to utilize Galectin-3 and HBME-1 proteins as biomarkers for thyroid cancer diagnosis, enabling earlier detection and reducing surgical interventions. The research has the potential to improve patient outcomes by accurately identifying patients at risk of cancer.
Researchers at Dana-Farber Cancer Institute have developed prototype drugs with powerful anti-diabetic effects without the severe side effects of current medications. The new compounds target PPAR-gamma, a metabolic regulator controlling fat cell development, and block phosphorylation to minimize risk.
A systematic review and meta-analysis of 21 studies found that biological agents for rheumatoid arthritis may increase the risk of skin cancer. The pooled risk showed a 45% higher likelihood of developing other types of skin cancer, while two studies indicated a 79% increased risk of melanoma.
Researchers found that cancers can become resistant to cetuximab by using an alternative signaling pathway activated by the ERBB2 protein, which is not affected by the drug. Combining cetuximab with ERBB2 inhibitors may be an effective therapy for these patients.
Scientists have developed 'transcription factor beacons' to quickly detect the activity of proteins controlling gene expression in cancer. The breakthrough technology may enable faster cancer diagnosis and the discovery of new cancer drugs.
Cells can switch between sender and receiver mode, inhibiting their own signals while allowing them to receive information from other cells. This mechanism could lead to the development of cancer drugs that target specific cell communications, potentially stopping uncontrollable proliferation.
A specific genetic alteration has been identified in epithelioid hemangioendothelioma (EHE), a rare but devastating vascular cancer. A new diagnostic test for EHE has also been developed using this finding.
A new study published in Neurology found that brain tumor patients who take valproic acid on top of standard treatment may live longer than those taking other epilepsy medications. The study showed an average three-month increase in survival for patients receiving valproic acid, but also noted increased risk of bleeding and infection.
Researchers have discovered a way to starve breast cancer cells by blocking their efficient amino acid delivery system. This approach could provide new treatment options for patients resistant to standard therapies.
The American Chemical Society honors Keith H. Gibson, Andrew J. Barker, and George L. Trainor for their contributions to personalized medicine and genetic sequencing. The trio developed a new drug that helped pioneer the era of 'personalized medicine' for cancer patients.
Scientists at the University of Strathclyde have developed a program to test plant extracts for their ability to stop ovarian cancer cells from growing. Initial tests show promising results, with several plant extracts killing tumor samples taken from cancer patients.
Researchers have imaged individual cancer cells and their routes as they spread in a mouse model of glioblastoma multiforme. The novel cryo-imaging technique provides unprecedented insights into how tumor cells invade and disperse.
The bivalent HPV vaccine has been shown to protect against anal HPV 16 and 18 infections, preventing nearly 84% of cases in women without prior exposure. The vaccine also offers cross-protective efficacy against other cancer-causing HPV types, suggesting a broader potential for prevention of HPV-associated cancers.
A U-M study found that nearly 17% of oncology nurses in outpatient settings were unintentionally exposed to chemotherapy drugs on their skin or eyes. The study emphasizes the importance of implementing nurse safety measures and adhering to national guidelines for preventing these incidents.
Researchers successfully created a computerized model of cancer cell metabolism, predicting which drugs are lethal to cancer cells' function and demonstrating efficacy in kidney cancer models. The approach holds promise for future investigations aimed at effective drug therapies for other types of cancer.
Researchers found that longer AI use was associated with increased heart disease and bone fractures, but lower rates of blood clots and womb cancer. Use of AIs for 2-3 years after initial treatment may explain the lack of overall survival benefit despite improved breast cancer recurrence
The U.S. Department of Energy's national laboratories enabled the discovery of a groundbreaking new drug treatment for malignant melanoma, with FDA-approved drug Zelboraf (vemurafenib) showing great promise in disrupting disease progression.
Researchers will analyze tumor samples from 100 patients with large intestine cancer or chronic lymphatic leukemia before and after drug treatment. The goal is to identify genetic mutations that contribute to treatment resistance, enabling the development of more effective cancer therapies.
Researchers used PET scans to measure estrogen-receptor blocking and binding in breast cancer patients. The study found that estrogen-receptor-blocking drugs such as tamoxifen were more effective than aromatase inhibitors in blocking the estrogen receptor in cancer cells.
Researchers used an 'opposites attract' algorithm to match drugs with diseases, finding potential benefits for lung cancer and inflammatory bowel disease. Preclinical tests confirmed the effectiveness of two existing drugs in treating these conditions.
A new computational method using genomic information predicts new uses for existing medicines, including treating Crohn's disease with prednisolone and inflammatory bowel diseases with topiramate. This approach could improve treatments, save time and money, and provide insights into disease progression and drug mechanisms.
A novel gene therapy approach combining with radiation therapy has been found to be safe and effective in treating glioblastoma multiforme, a deadly form of brain cancer. The treatment stimulates an immune response against the tumor, producing an 'immunogene therapy' effect.
Researchers at Stanford University have developed a new dual-action protein that effectively prevents the formation of blood vessels by targeting two key chemical receptors. This breakthrough could lead to more effective cancer treatments and potentially benefit diseases such as macular degeneration.